These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 20504257)

  • 1. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
    Vincenzi B; Napolitano A; Frezza AM; Schiavon G; Santini D; Tonini G
    Pharmacogenomics; 2010 Jun; 11(6):865-78. PubMed ID: 20504257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
    Carter NJ; Keam SJ
    Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trabectedin in soft tissue sarcomas.
    Brodowicz T
    Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
    Le Cesne A
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical and clinical results with the natural marine product ET-743.
    D'Incalci M; Jimeno J
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trabectedin for the management of soft-tissue sarcoma.
    Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
    van Kesteren Ch; de Vooght MM; López-Lázaro L; Mathôt RA; Schellens JH; Jimeno JM; Beijnen JH
    Anticancer Drugs; 2003 Aug; 14(7):487-502. PubMed ID: 12960733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.
    Schöffski P; Dumez H; Wolter P; Stefan C; Wozniak A; Jimeno J; Van Oosterom AT
    Expert Opin Pharmacother; 2008 Jun; 9(9):1609-18. PubMed ID: 18518789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabectedin in soft tissue sarcomas.
    Petek BJ; Loggers ET; Pollack SM; Jones RL
    Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trabectedin.
    Chuk MK; Balis FM; Fox E
    Oncologist; 2009 Aug; 14(8):794-9. PubMed ID: 19684073
    [No Abstract]   [Full Text] [Related]  

  • 12. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
    Gordon EM; Sankhala KK; Chawla N; Chawla SP
    Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
    Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
    Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
    Roylance R; Seddon B; McTiernan A; Sykes K; Daniels S; Whelan J
    Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):572-6. PubMed ID: 17624747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique features of trabectedin mechanism of action.
    Larsen AK; Galmarini CM; D'Incalci M
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
    Gennigens C; Jerusalem G
    Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin: an anticancer drug from the sea.
    Ganjoo KN; Patel SR
    Expert Opin Pharmacother; 2009 Nov; 10(16):2735-43. PubMed ID: 19743937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biology of ovarian cancer and trabectedin mechanism of action.
    Ray-Coquard I
    Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
    Cuevas C; Francesch A
    Nat Prod Rep; 2009 Mar; 26(3):322-37. PubMed ID: 19240944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin mechanism of action and platinum resistance: molecular rationale.
    Ray-Coquard I
    Future Oncol; 2017 Oct; 13(23s):17-21. PubMed ID: 29020822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.